It is apparent from the animal and human studies which reviewed that CHRNB2 is an important gene in maintaining nicotine dependence and contributes to significant symptoms of nicotine withdrawal. Smoking cessation therapies targeted to individuals with specific alterations in this gene may provide relief from the affective symptoms that promote relapse and continued use. However, additional research is necessary to provide the evidence base for this clinical approach.
